Canadian Paediatric Immunization Awareness
Safety and Schedules
Trusted Guidance for Safe, Timely Immunization
Canada's immunization program is backed by decades of research, rigorous safety monitoring, and recommendations from leading public health experts. Here's everything you need to know.
Canadian Immunization Guide
A comprehensive 56-chapter resource developed by Public Health Agency of Canada. Covers all vaccines, schedules, safety, and special populations.
Read the Guide →Immunization Schedule
Know exactly which vaccines are recommended at each age — from birth through adulthood. Built around when children are most vulnerable and vaccines are most effective.
View Full Schedule →Vaccine Safety & Monitoring
Every approved vaccine in Canada undergoes multi-stage safety evaluation before and after licensing. Learn how pharmacovigilance protects you after vaccination.
Learn About Safety →Canadian Childhood Immunization Schedule
Based on the Public Health Agency of Canada's recommended schedule. Always confirm current dosing with your healthcare provider.
| Age | Vaccines Recommended | Notes |
|---|---|---|
| Birth | Hep B (if mother is carrier) | Given in hospital when indicated |
| 2 Months | DTaP-IPV-Hib Pneumococcal (PCV) Rotavirus Meningococcal C | First of a series of doses; may be given at same visit |
| 4 Months | DTaP-IPV-Hib Pneumococcal (PCV) Rotavirus Meningococcal C | Second doses |
| 6 Months | DTaP-IPV-Hib Pneumococcal (PCV) Rotavirus (if applicable) Influenza (annual) | Flu vaccine recommended from 6 months onward, annually |
| 12 Months | MMR Varicella Meningococcal C Pneumococcal (PCV) | MMR + Varicella can be given as MMRV combination |
| 18 Months | DTaP-IPV-Hib Hep A (some provinces) | Boosters; schedule varies slightly by province |
| 4–6 Years | DTaP-IPV MMR (2nd dose) Varicella (2nd dose) | Before school entry; important booster doses |
| Grade 4–6 | HPV (2–3 doses) Meningococcal (ACYW135) Hep B (if not completed) | School-based program; HPV protects against cancer-causing strains |
| 14–16 Years | Tdap booster Meningococcal (if not given) | Tetanus-diphtheria-pertussis booster recommended every 10 years thereafter |
| Adults | Influenza (annual) Tdap (every 10 yrs) Shingles (50+) Pneumococcal (65+) COVID-19 (as recommended) | Adult schedules depend on risk factors, travel, and age |
How Canada Ensures Vaccine Safety
Vaccine safety in Canada is a multi-layered system — from laboratory testing through clinical trials to ongoing post-market surveillance. No vaccine is approved without extensive evidence of safety and effectiveness.
✅ Before a Vaccine is Approved
- Laboratory and preclinical studies to assess biological activity
- Phase I, II, and III clinical trials involving thousands of participants
- Review by Health Canada's regulatory team for safety and efficacy data
- Approval issued only when benefits are shown to clearly outweigh risks
- Lot-by-lot testing of every vaccine batch before distribution
🔍 After Approval — Ongoing Monitoring
- Post-market surveillance through Canada's AEFI reporting system
- Healthcare providers report any adverse events following immunization
- International data sharing with WHO and global health networks
- Continuous review; vaccines can be modified or withdrawn if new concerns arise
- Public reporting of safety findings through Health Canada and PHAC
Vaccine Safety: What Parents Ask
Answers based on evidence from Canadian and international public health authorities.
Allergic reactions to vaccines can happen but are extremely rare — occurring in approximately 0.65 to 1.45 reactions per million doses. Most people experience only mild side effects such as redness, swelling at the injection site, or a low-grade fever. Clinics are equipped to handle reactions, and recipients are typically monitored for 15 minutes after vaccination.
Source: CDC — Questions Parents May Ask
Every ingredient in a vaccine — including preservatives, adjuvants, and stabilizers — is tested extensively for safety and must be present in amounts far below any harmful threshold. Regulatory agencies like Health Canada evaluate ingredient safety before approval and continue monitoring after market release.
Source: CDC — Questions Parents May Ask
Some vaccines include small amounts of aluminum salts as adjuvants — substances that help strengthen the immune response. The aluminum exposure from all childhood vaccines combined is actually less than what infants receive through breast milk or formula over the same period. Aluminum adjuvants have a decades-long safety record.
Thimerosal, a mercury-containing preservative, was removed from most routine childhood vaccines in Canada and the United States decades ago. Studies conducted both before and after its removal found no evidence of harm. The type of mercury in thimerosal (ethylmercury) is processed differently by the body than the environmental mercury that accumulates in fish.
Extensive research involving millions of children across multiple countries shows no link between vaccines and chronic health conditions such as autism or autoimmune diseases. The original 1998 study that suggested a link between MMR vaccine and autism was retracted due to serious methodological flaws and ethical violations. Dozens of subsequent large-scale studies have confirmed vaccines do not cause autism.
Source: CDC — Questions Parents May Ask
Yes — a minor illness without fever (such as a runny nose or mild cold) is generally not a reason to delay vaccination. Severe illness or high fever may warrant rescheduling until the child has recovered. Your healthcare provider will assess on a case-by-case basis at the time of the appointment.
Source: CDC — Questions Parents May Ask
Explore the Canadian Immunization Guide
56 chapters of evidence-based immunization guidance — updated continuously as new evidence emerges.
Part 1: Key Immunization Information
Covers immunization in Canada, benefits, schedules, administration practices, storage, timing, and basic immunology.
Read Part 1 →Part 2: Vaccine Safety
Covers pharmacovigilance, contraindications, anaphylaxis management, and adverse events following immunization (AEFI).
Read Part 2 →Part 3: Specific Populations
Guidance for adults, pregnant women, immunocompromised individuals, premature infants, travellers, and more.
Read Part 3 →We've Answered the Most Common Vaccine Doubts
Read all 17 answers — from ingredients to schedules, allergies to autism myths.